Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

A federal judge in Massachusetts has ruled that hundreds of grants terminated by the National Institutes of Health (NIH) must be restored immediately, the latest legal victory for groups challenging ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Gökhan Hotamışlıgil, M.D., Ph.D., has secured about $39 million from a Turkish investment group to support the next 10 years ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...